The exosome question: signal without the cell.

If you have spent any time in the regenerative-medicine literature in the last five years, you have run into exosomes. They are extracellular vesicles, tiny membrane-bound packets, 30 to 150 nanometres across, released by almost every cell in the body, including mesenchymal stem cells. They carry proteins, lipids, mRNA and microRNA. They mediate a meaningful share of the paracrine signalling that biologists used to attribute to the stem cell itself.

Why the question is interesting

If exosomes are responsible for most of the therapeutic effect of an MSC infusion, and if exosomes can be produced, characterised and dosed without infusing live cells, the implications are real. You could dose without the harvest. You could store at room temperature. You could deliver topically or by aerosol where the target tissue allows it. You could decouple the clinical effect from the practical complexity of expanding and releasing a living cell product.

The trial data is genuinely interesting. There are signals in tendon healing, skin biology, post-stroke recovery and, with caveats, in chronic inflammatory conditions. Our research consultant Dr. Warut Tulalamba tracks the published literature on this for the clinic, and we have an internal protocol review every quarter.

Why we are cautious

The honest read is that exosome therapy is at an earlier stage of clinical maturity than people marketing it imply. The reasons are unglamorous and technical. Exosome products vary widely between manufacturers, the producing cell line, the harvest method, the purification standard, the characterisation panel, and the field has not converged on a single quality standard the way ISCT criteria did for MSCs themselves.

The downstream problem is that two exosome products labelled the same way can contain different signalling cargo, and a clinic that does not run its own characterisation cannot know what it is administering. This is the same chain-of-custody problem covered in autologous vs allogeneic, why our chain of custody matters, in a faster-moving form.

Where it fits in our practice today

We use exosome adjuncts in two contexts where the evidence is most defensible: topical post-procedure recovery in our aesthetics protocols and a small number of dermatological and tendon cases where the clinical objective is well-matched to the published signal. Beyond those, we treat exosome therapy as research, not as a replacement for the MSC programme.

The MSC mechanism itself, homing, immunomodulation, paracrine signalling at the source, is covered in how effective is MSC. Cell-free therapy is part of where regenerative medicine is going. It is not yet, in our reading of the evidence, where regenerative medicine reliably is.

What changes the read

Two things would move our use of exosomes from adjunct to primary. One: convergence on a quality standard, the way ISCT did for MSCs, with reliable characterisation that any competent laboratory can run. Two: well-powered randomised trials with clinical endpoints, not just biomarker shifts. Neither is far away. Both are not yet here.

We will keep watching. When the evidence moves, the practice will move with it.